Login to Your Account



Solstice Closes $18M Series A; Raises Stakes in RNAi Delivery

By Jennifer Boggs
Managing Editor

Monday, January 7, 2013
The promise of RNAi – the idea that specific genes can be pinpointed and silenced to treat disease – has loomed large on biopharma's radar for the past decade, even netting a 2006 Nobel to RNAi discoverers Craig Mello and Andrew Fire.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription